Q2 2017 Earnings Estimate for Eli Lilly and Company Issued By Leerink Swann (NYSE:LLY)
Eli Lilly and Company (NYSE:LLY) – Research analysts at Leerink Swann raised their Q2 2017 earnings per share (EPS) estimates for shares of Eli Lilly and Company in a research report issued on Monday. Leerink Swann analyst S. Fernandez now forecasts that the company will post earnings of $1.04 per share for the quarter, up from their previous forecast of $1.03. Leerink Swann currently has a “Outperform” rating on the stock. Leerink Swann also issued estimates for Eli Lilly and Company’s Q3 2017 earnings at $1.00 EPS, FY2017 earnings at $4.09 EPS, FY2019 earnings at $4.85 EPS, FY2020 earnings at $5.23 EPS and FY2021 earnings at $5.58 EPS.
Eli Lilly and Company (NYSE:LLY) last released its earnings results on Tuesday, April 25th. The company reported $0.98 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.96 by $0.02. The firm had revenue of $5.23 billion for the quarter, compared to analysts’ expectations of $5.22 billion. Eli Lilly and Company had a return on equity of 26.64% and a net margin of 10.13%. The business’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.83 EPS.
Several other brokerages have also issued reports on LLY. Piper Jaffray Companies reiterated a “buy” rating and issued a $100.00 price target on shares of Eli Lilly and Company in a report on Monday, April 17th. Credit Suisse Group reiterated a “buy” rating on shares of Eli Lilly and Company in a report on Tuesday, March 21st. Argus lowered Eli Lilly and Company from a “buy” rating to a “hold” rating and raised their target price for the company from $64.18 to $81.00 in a report on Thursday, April 27th. They noted that the move was a valuation call. Jefferies Group LLC restated a “buy” rating and issued a $93.00 target price on shares of Eli Lilly and Company in a report on Thursday, June 22nd. Finally, Sanford C. Bernstein restated an “outperform” rating and issued a $88.00 target price on shares of Eli Lilly and Company in a report on Sunday, May 21st. Two analysts have rated the stock with a sell rating, six have given a hold rating and eleven have issued a buy rating to the company. Eli Lilly and Company presently has an average rating of “Hold” and an average target price of $87.78.
Shares of Eli Lilly and Company (NYSE:LLY) opened at 84.02 on Wednesday. The company has a market cap of $88.75 billion, a PE ratio of 40.63 and a beta of 0.35. Eli Lilly and Company has a 1-year low of $64.18 and a 1-year high of $86.72. The firm has a 50-day moving average price of $80.49 and a 200 day moving average price of $79.95.
A number of institutional investors have recently bought and sold shares of LLY. First Command Financial Services Inc. boosted its position in Eli Lilly and Company by 7.3% in the first quarter. First Command Financial Services Inc. now owns 1,227 shares of the company’s stock valued at $103,000 after buying an additional 84 shares during the last quarter. Heritage Trust Co acquired a new position in Eli Lilly and Company during the first quarter valued at approximately $135,000. Point72 Asia Hong Kong Ltd boosted its position in Eli Lilly and Company by 237.4% in the first quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock valued at $148,000 after buying an additional 1,239 shares during the last quarter. LeJeune Puetz Investment Counsel LLC acquired a new position in Eli Lilly and Company during the fourth quarter valued at approximately $136,000. Finally, Penserra Capital Management LLC boosted its position in Eli Lilly and Company by 9.5% in the first quarter. Penserra Capital Management LLC now owns 2,024 shares of the company’s stock valued at $170,000 after buying an additional 176 shares during the last quarter. Institutional investors and hedge funds own 75.41% of the company’s stock.
In related news, VP Michael J. Harrington sold 22,833 shares of the business’s stock in a transaction dated Friday, June 9th. The stock was sold at an average price of $79.97, for a total transaction of $1,825,955.01. Following the completion of the transaction, the vice president now directly owns 62,056 shares in the company, valued at $4,962,618.32. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, major shareholder Lilly Endowment Inc sold 210,000 shares of the business’s stock in a transaction dated Thursday, June 22nd. The stock was sold at an average price of $84.43, for a total value of $17,730,300.00. Following the transaction, the insider now owns 124,265,804 shares of the company’s stock, valued at $10,491,761,831.72. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 474,733 shares of company stock valued at $39,634,487. 0.20% of the stock is owned by company insiders.
The firm also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Tuesday, August 15th will be given a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.48%. The ex-dividend date of this dividend is Friday, August 11th. Eli Lilly and Company’s payout ratio is 100.48%.
Eli Lilly and Company Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.